Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Update

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) was the target of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 5,460,000 shares, a growth of 23.0% from the August 15th total of 4,440,000 shares. Based on an average daily trading volume, of 444,800 shares, the short-interest ratio is currently 12.3 days.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Vanguard Group Inc. lifted its holdings in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 2.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,001,836 shares of the company’s stock after acquiring an additional 26,854 shares during the quarter. Vanguard Group Inc. owned approximately 3.59% of Reviva Pharmaceuticals worth $3,787,000 at the end of the most recent reporting period. 63.18% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of Reviva Pharmaceuticals in a research report on Thursday, July 11th. Benchmark restated a “speculative buy” rating and set a $17.00 price objective on shares of Reviva Pharmaceuticals in a research report on Monday, August 26th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Reviva Pharmaceuticals in a research report on Friday, August 16th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.33.

Reviva Pharmaceuticals Price Performance

Shares of RVPH traded up $0.04 during mid-day trading on Tuesday, reaching $1.21. The company had a trading volume of 14,426 shares, compared to its average volume of 362,978. The company has a market capitalization of $33.78 million, a P/E ratio of -0.74 and a beta of -0.10. Reviva Pharmaceuticals has a twelve month low of $0.60 and a twelve month high of $6.80. The company’s 50-day moving average is $1.07 and its 200-day moving average is $1.95.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. As a group, equities analysts expect that Reviva Pharmaceuticals will post -0.98 EPS for the current fiscal year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.